Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports

OBJECTIVE: Despite the promising efficacy and tolerability of alectinib in treating advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), the role of alectinib in neoadjuvant setting remains understudied in ALK-rearranged resectable lung cancer. METHODS: Our report c...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Liang, Gao, Shuhong, Tong, Li, Meng, Qiyi, Zhou, Shijie, Yu, Daping, Dong, Yujie, Liu, Zhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318538/
https://www.ncbi.nlm.nih.gov/pubmed/37409244
http://dx.doi.org/10.3389/fonc.2023.1120511

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318538/
https://www.ncbi.nlm.nih.gov/pubmed/37409244
http://dx.doi.org/10.3389/fonc.2023.1120511

Ejemplares similares